Boehringer Ingelheim and WHO Foundation Launch Global Collaboration on Obesity and Metabolic Health

Boehringer Ingelheim and the WHO Foundation have announced a three-year global collaboration aimed at accelerating progress in tackling obesity and associated metabolic diseases, particularly in resource-limited regions. The initiative is supported by a $5 million contribution from Boehringer Ingelheim over three years.

The partnership intends to strengthen health systems' capacity to monitor and manage obesity and related conditions, such as cardiovascular disease, kidney disease, and diabetes. This effort addresses the growing global challenge of obesity, with over 2.5 billion adults and more than 390 million children and adolescents classified as overweight in 2022, according to the World Health Organization.

Through this collaboration, the WHO Foundation will support the WHO's "Acceleration Plan to Stop Obesity (2022–2030)". This plan encourages member states to translate commitments into action through evidence-based measures and systemic changes. The project aims to integrate obesity care with the management of non-communicable diseases and involve patients in policy discussions.

Representatives from Boehringer Ingelheim highlighted that effectively addressing obesity requires health systems that recognize shared risk factors and provide coordinated, long-term care. The collaboration seeks to translate global goals into practical and sustainable changes for both individuals and healthcare systems.

This new initiative builds upon previous partnerships between Boehringer Ingelheim and the WHO Foundation, including efforts to strengthen suicide prevention systems in the Americas. The overarching goal is to promote a more comprehensive approach to obesity and metabolic health, ultimately integrating chronic disease care into resilient primary healthcare systems.